|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Clustering also defined a hypermethylated luminal-enriched tumor cluster 3 that gene ontology analysis revealed to be enriched for homeobox and other developmental genes (ASCL2, DLK1, EYA4, GAS7, HOXA5, HOXA9, HOXB13, IHH, IPF1, ISL1, PAX6, TBX1, SOX1, and SOX17).
|
25287138 |
2014 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Interestingly, similar to stem cells in normal tissues, Lgr5(+) cells were often restricted to the base of the tumor glands, and such Lgr5(+) restriction was associated with high levels of intestinal stem cell markers such as EPHB2, OLFM4, and ASCL2.
|
24340024 |
2013 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In addition, knockdown of hASH2 inhibited tumor cell proliferation.
|
18245475 |
2008 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
Biomarker
|
disease |
BEFREE |
WiNTRLINC1 is a long non-coding RNA (lncRNA) that positively regulates the Wnt pathway via achaete-scute complex homolog 2 (ASCL2) in colorectal cancer.
|
31549316 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
Biomarker
|
disease |
BEFREE |
Human achaete scute homolog 2 (HASH2) and its murine ortholog MASH2 are potential targets for colorectal cancer immunotherapy.
|
30682058 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
Biomarker
|
disease |
BEFREE |
R-spondin1/Wnt-enhanced Ascl2 autoregulation controls the self-renewal of colorectal cancer progenitor cells.
|
29886802 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer.
|
25277775 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the Ascl2/CDX2 axis may serve as a potential therapeutic target in colorectal cancer.
|
26307678 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
Biomarker
|
disease |
BEFREE |
Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain.
|
20479215 |
2010 |
|
Colon Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
WiNTRLINC1 was not significantly associated with prognostic factors in colon cancer and other lncRNAs, while the WiNTRLINC1/ASCL2/c-Myc signatures were unique to young-onset colon cancer with differentiated histology.
|
31549316 |
2019 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Meanwhile, we also revealed that trophoblast-expressed Rbpj in EPC facilitates Mash2's transcriptional activity, promoting the specification of Tpbpα-positive trophoblasts, which differentiate into trophoblast subtypes responsible for interstitial and endovascular invasion at the later stage of placental development.
|
31165749 |
2019 |
|
Colon Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The transcription factor Ascl2 (Wnt target gene) is fate decider of intestinal cryptic stem cells and colon cancer stem cells.
|
29886802 |
2018 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The intestinal stem cell regulating gene ASCL2 is required for L1-mediated colon cancer progression.
|
29551399 |
2018 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Together, our results suggest that bufalin arrests invasion and metastasis and that its mechanism of action may involve down-regulating Wnt/ASCL2 expression.
|
29805736 |
2018 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
ASCL2 expression contributes to gastric tumor migration and invasion by downregulating miR223 and inducing EMT.
|
30106147 |
2018 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Ascl2 activation by YAP1/KLF5 ensures the self-renewability of colon cancer progenitor cells.
|
29312609 |
2017 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Specifically, ASCL2 enhanced the invasion and metastasis of CRC cells in vitro and expression of ASCL2 correlated with distant metastasis, tumour size and poor overall survival in CRC patients.
|
25866254 |
2015 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Depletion of ASH2 ameliorated cancer cell migration and invasion in an MMP9-dependent manner.
|
25746000 |
2015 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
However, its involvement in colon cancer and downstream molecular events is largely undefined; in particular, the mechanism by which Ascl2 regulates the plasticity of epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) programs in colon cancer cells remains unknown.
|
25371200 |
2014 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
|
29746925 |
2018 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Now we demonstrated that CD133<sup>+</sup>/CD44<sup>+</sup> cell population from HT-29 or Caco-2 cells exhibited cancer stem cell (CSC) properties with highly expressed Ascl2, which is related to the Hippo signaling pathway.
|
29312609 |
2017 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Depletion of ASH2 ameliorated cancer cell migration and invasion in an MMP9-dependent manner.
|
25746000 |
2015 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Ascl2 and Lgr5 were expressed in 85% and 74% of cancers respectively, and expression was positively correlated (p=0.003).
|
22637696 |
2013 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Together, our results suggest that bufalin arrests invasion and metastasis and that its mechanism of action may involve down-regulating Wnt/ASCL2 expression.
|
29805736 |
2018 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
The data suggested that the expression of ASCL2 was highest in metastatic tumors, among adjacent normal tissues, primary gastric tumors and gastric metastatic tumors.
|
30106147 |
2018 |